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Clinical review
Balancing benefits and harms: the example of
non-steroidal anti-inflammatory drugs
Paul Dieppe, Christopher Bartlett, Peter Davey, Lesley Doyal, Shah Ebrahim
To provide safe and effective interventions for people,
reliable and valid evidence is needed. This is most eas-
ily produced by undertaking trials in samples of people
who are as homogeneous as possible and applying the
results to similar, well defined groups of patients. To be
equitable, however, appropriate care needs to be
provided for everyone in the diverse community using
health services. Therefore, there is a tension between
obtaining scientific evidence that is reliable but which
can be applied only to a small subset of the population,
and distributive justice that requires that all in need are
treated equally appropriately.
Drugs have potential harms as well as benefits.
Doctors would like to be able to balance any risks
against benefits to derive a therapeutic ratio for each
patient, but this is difficult. Formal trials can tell a lot
about the efficacy of a drug in a specific context, but
unless they are huge and pragmatic they tell less about
a drug’s toxicity. Post-marketing surveillance may
uncover more information on toxicity, but the data
usually lack sufficient detail to lead to an understand-
ing of the determinants of adverse reactions.
Furthermore, extrapolation of the efficacy or toxicity of
a drug in one disease or group of patients to those
associated with different diseases or groups can be dif-
ficult and misleading.
We examined aspects of these problems in the con-
text of one commonly prescribed class of drugs—non-
selective, non-steroidal anti-inflammatory agents
(NSAIDs)—and their use in the management of joint
pain.
Risks and benefits of NSAIDs in treating
joint pain
We compared the types of patients in whom trials of
non-selective NSAIDs are conducted with those who
receive the drugs in practice. Then we examined the
prevalence and associations of adverse events in these
two groups.
Methods
As NSAIDs are primarily used to treat arthritic pain, we
studied trials of these drugs in patients with
osteoarthritis, the commonest form of arthritis in the
community.1 We collected a comprehensive database
of such trials (described elsewhere2) and examined the
inclusion and exclusion criteria to determine the sort
of people the trial data were derived from. We also
looked at the reporting of adverse events. To compare
this with the utilisation and toxicity of NSAIDs in the
community, we explored the medicines monitoring
database in Scotland (www.dundee.ac.uk/memo).3 This
large database links all prescriptions in the area to hos-
pital admission records and data on disease, which
helps to determine who is being given the drugs and
what adverse events have been experienced.
Results
From the comprehensive dataset of trials on NSAIDs
in osteoarthritis,2 we identified 219 eligible papers
describing randomised trials for the treatment of oste-
oarthritis with a non-selective NSAID in at least one
arm. These papers were stratified according to the
number of patients in each arm ( < 100, 100-199,
≥ 200). A random sample of 11% of each of the three
strata was selected, by using a list of random numbers,
to produce a representative sample of 25 trials for
detailed study (14 trials had < 100 patients in each
arm, five trials had 100-199, and six trials had ≥ 200).
From these papers we extracted the inclusion and
exclusion criteria and adverse events. The trials were
relatively small (median 67 patients) and brief (mostly
≤ 6 weeks). Overall, 68.5% of the participants were
women, aged 62 (SD 5) years; those over 75 were
Summary points
High quality scientific evidence from drug trials
may not be generalisable to everyone likely to
take the drug
Minority groups and older people are often
excluded from trials
Drugs tend to be used for a wider range of
indications than those for which they are trialed
People at risk of adverse events are often
deliberately excluded from trials
Benefits and harms of drugs are not measured on
comparable scales
Large databases linking prescribing to hospital
data and other health records are needed to
assess the relative benefits and harms of drugs
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excluded from most trials. Ethnicity was not generally
reported. The participants were mainly patients known
to have benefited from NSAIDs and in whom the risk
of adverse events was small. Thus those with toxicity to
NSAIDs or at risk of gastrointestinal or renal problems
were specifically excluded. Dropout rates due to
gastrointestinal problems such as dyspepsia were
reported in about two thirds of the trials, but serious
gastrointestinal events such as bleeding were poorly
reported.Other serious adverse events (including renal
toxicity) were not mentioned in any trial, and the
reporting of outcomes was seldom related to age, sex,
or ethnicity.
Community cohort
The medicines monitoring database contains a cohort
of 131 410 patients who were prescribed non-selective
NSAIDs between 1989 and 1996.3 Over half (58%) of
the cohort was female. Their mean age was 49.7 (range
− 10 to ≥ 90), and 19 013 (14.5%) were aged over 75.
From the number of prescriptions written for
individual patients, we examined the use of NSAIDs
and related that to hospital admission for gastrointesti-
nal or renal problems. Prescribing was common in all
age groups, including those over 75, who were
excluded from the trials, and in people at high risk of
gastrointestinal or renal problems. The risk of hospital
admission for gastrointestinal or renal events increased
with increasing age, as well as with increasing use of
NSAIDs (table). We calculated the events rate in high
risk patients (elderly patients and those with coexisting
gastrointestinal or renal disease) and low risk patients
(those included in the trials). The relative risk of admis-
sion for an acute gastrointestinal event was about four
times greater in high risk patients and for a renal event
about double.
Validity of trials
Much attention is given to the internal validity of trials
(whether the data are “true”) and less to the external
validity of trial data (whether the data on drugs are
generalisable to the population to whom they are to be
prescribed). Our study concerned the external validity
of trials of conventional NSAIDs. The basic issue we
addressed was diversity—that is, the likelihood of varied
effectiveness or adverse events of NSAIDs in different
patients.
From our examination of the literature on diversity
(including age, sex, gender, and ethnicity) we conclude
that there is a complex overlap between the many dif-
ferent factors that might lead to social exclusion and to
exclusion from either trials or equitable health care.4
For example, older people are often excluded from
trials (the rationale often being that they are more vul-
nerable to comorbidities, adverse drug reactions, and
problems with consenting), and older women are
noticeably under-represented in trials of many drugs,
despite their larger numbers in most developed socie-
ties.5 6 Similarly, ethnic minorities are often excluded
(sometimes on the basis of language), and there is a
clear overlap between ethnic minorities, economic dis-
advantage, and social exclusion.7
Drugs tested in one condition are often prescribed
to people with another condition. We examined trials
of NSAIDs in the management of osteoarthritis
because that is the commonest cause of joint pain in
the community and the main condition for which these
drugs are marketed and used.1 8 Although we found
that some aspects of the reporting of these trials was
poor, the quality of the trials was generally good, and
most of them were carried out on patients with well
characterised osteoarthritis, in whom comorbidities
were absent (by exclusion). In the population cohort
that we studied the situation was different. It is likely
that many of those who were prescribed an NSAID had
osteoarthritis, but many will have had other causes of
pain, including inflammatory forms of arthritis such as
rheumatoid arthritis or systemic lupus erythematosus.
Similarly, many of those patients will have had comor-
bidities. Unfortunately, we do not know why the drugs
were prescribed to people in the cohort or the level of
comorbidity and coprescribing. As a result we cannot
make inferences about the mechanisms of harms;
although all the patients used NSAIDs, we cannot
attribute all the events to NSAIDs. What is clear is that
the harms observed in practice were different from
those reported in the trials, on which the use of the
drugs was based, and that there was a dose relation
between risk and drug use.
Admission to hospital for acute gastrointestinal problem or acute renal failure in
131 410 patients receiving 928 888 prescriptions for non-steroidal anti-inflammatory
drugs (NSAIDs). Data from Medicines Monitoring Unit database, 1989-963
Risk factor
Relative risk (95% CI)*
Gastrointestinal event Renal event
Use of non-selective NSAIDs†:
None 0 0
Low (1-25%) 1.04 (0.93 to 1.15) 1.19 (0.98 to 1.44)
Medium (26-50%) 1.26 (1.13 to 1.41) 1.38 (1.14 to 1.68)
High (>50%) 1.48 (1.38 to 1.60) 1.69 (1.48 to 1.92)
Age:
30-39 0.65 (0.57 to 0.75) 0.61 (0.35 to 1.07)
40-49 0.84 (0.75 to 0.94) 0.57 (0.35 to 0.94)
50-59 0 0
60-69 1.09 (0.99 to 1.2) 2.31 (1.68 to 3.18)
70-79 1.20 (1.09 to 1.32) 4.70 (3.49 to 6.33)
≥80 1.61 (1.46 to 1.78) 8.79 (6.55 to 11.8)
*Adjusted for age, sex, Carstairs index of deprivation, and use of other drugs.
†Mainly ibuprofen, diclofenac, and naproxen. Use based on numbers of days per year that patient would
take drug if all tablets prescribed were taken.
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Pharmaceutical companies promote NSAIDs by
highlighting both the benefits and the harms from
their use. For example, an advertisement may contain
an image of an older person enjoying pain free activity
that is contrasted with the image of an ulcerated stom-
ach, if protection of the gastrointestinal tract is the
marketing angle.
Adverse event reporting
The recent literature on adverse events associated with
NSAIDs has focused on gastrointestinal problems, with
less attention to renal and cardiovascular toxicity (fluid
retention, hypertension, impairment of renal function),
despite these well known problems.9–13 Some of the
early literature gave conflicting messages about the
association between NSAIDs and renal disease14; but
our results are consistent with four large case-control
studies from the past 15 years, in which patients, largely
elderly, admitted to hospital with renal impairment
were 2-4 times more likely to have used NSAIDs than
control patients.15–18
Exclusion from randomised controlled trials of
patients at risk from renal impairment misinforms
practitioners in two important ways: by weakening
their awareness of the risk of renal failure associated
with NSAID and by failing to provide relevant
information about the relative risks from different
NSAIDs. Interest in gastrointestinal problems may be
partly due to the pharmaceutical industries’ endeav-
ours to produce selective NSAIDs, or “coxibs,” that
might be less toxic to the gastrointestinal tract.19–21 We
have studied only the non-selective NSAIDs, but we
have shown that admissions to hospital for renal failure
and gastrointestinal events were increased in those
using the drugs, particularly older people and those
with known risk factors.
Risk benefit ratio
These findings illustrate some of the difficulties in try-
ing to balance the potential risks of an intervention
with its potential benefits. Data from trials on efficacy
can provide estimates of the absolute effects of
treatment by numbers needed to treat or numbers
needed to harm. But these treatment effects are
averages derived from highly selected, relatively small,
and restricted groups of patients who are unlikely to be
representative of the population that will use the drugs.
A further concern is that numbers needed to treat and
numbers needed to harm are often not measured on
comparable scales of benefit and harm. If a drug
clearly has major life saving benefits, then it is likely
that these will outweigh relatively uncommon adverse
effects. In the case of NSAIDs, however, comparing
improvements in joint pain and stiffness with the
uncommon risks of hospital admission for gastrointes-
tinal bleeding or renal failure is not straightforward.
Similarly, it is clear that assuming that the risk of harm
is relatively stable whereas that of benefit depends on
the severity of the disease, cannot be applied in this
sort of case, due to the likely effects of disease
indication, age, and comorbidity on the adverse events.
Different indications
We looked specifically at trials of NSAIDs in
osteoarthritis. Many trials have also been done in rheu-
matoid arthritis, but relatively few in other, less
common rheumatic diseases such as systemic lupus
erythematosus. Theoretically, renal adverse events
could be greater in patients with rheumatoid arthritis,
and particularly those with systemic lupus erythemato-
sus, than in those with osteoarthritis, as these and other
systemic rheumatic conditions can affect the kidneys
and cardiovascular systems directly.22 23 One problem
with most of the less common inflammatory rheumatic
diseases, in which there are few trials, is that NSAIDs
are not specifically approved for use in these
conditions but are nevertheless prescribed routinely to
patients with them if they have joint pain, and there is
no way of knowing from the trial data whether that is
damaging to the kidneys or cardiovascular system.
Similarly, both gastrointestinal and renal adverse
events are affected by coprescribing, including steroids
and analgesics, both of which are commonly used for
arthritis.24 Again, the importance of coprescribing can-
not be certain from the trial data alone.
The need for record linkage
Our study was only possible because of access to the
Medicine Monitoring Unit’s database, in which
prescribing is linked to hospital data through collabo-
ration with NHS Information Services (ISD) in
Edinburgh. The use of this sort of record linkage is
particularly valuable for the examination of adverse
events, but if reliable information is to be obtained,
large datasets that can link prescribing data to other
health records are needed. In many countries, record
linkage has been made more difficult with the
introduction of data protection legislation.25 26 The best
way to get more reliable post-marketing data on drug
toxicity in particular is by establishing more datasets
like the one in Tayside, so that adverse events can be
related to patient characteristics, and by performing
large randomised trials using routine data for follow
up.27
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Antidepressants and suicide: what is the balance of benefit
and harm
David Gunnell, Deborah Ashby
Prescribing of antidepressants has increased greatly in
England and elsewhere in recent years.1–3 This increase
has coincided with a fall in rates of suicide, leading
some researchers to suggest a causal association.2 4–6
Meanwhile, others are concerned that antidepressants
may precipitate suicidal behaviour.7 8 A recent review
of evidence from paediatric trials by the Committee on
Safety of Medicines in Britain led to most selective
serotonin re-uptake inhibitors (SSRIs) being contrain-
dicated in people aged younger than 18.9 So how safe
are they? In this article, we assess the data on the risks
and benefits.
Is increased prescribing linked to
reduced suicide rates?
SSRIs and tricyclic antidepressants account for over
90% of antidepressant prescribing in Britain. System-
atic reviews confirm that both these classes of
antidepressant are effective in adults,10 although SSRIs
are better tolerated by patients.11 The effectiveness of
antidepressants in childhood and adolescence is less
clear.12
As depression is the main psychiatric condition
leading to suicide, it seems reasonable to infer that rises
in antidepressant prescribing, which indicate improved
management of depression, should have a beneficial
effect on suicide rates. Indeed, an intervention to
improve general practitioners’ management of depres-
sion in a Swedish community resulted in increased
antidepressant prescribing and a short term reduction
in suicide.13
Surprisingly, direct evidence that antidepressants
prevent suicide is hard to find. A meta-analysis of
data on the SSRI fluoxetine, funded by its manu-
facturer, found no evidence that suicidal acts were less
frequent among adults taking antidepressants; the
pooled incidences were 0.3% for fluoxetine, 0.2% for
placebo, and 0.4% for tricyclics.14 In the most compre-
hensive synthesis of data from randomised trials,
Summary points
Concern is growing that serotonin reuptake
inhibitors (SSRIs) may precipitate suicidal
behaviour, especially in children
Reassuringly, although antidepressant prescribing
in Britain has more than doubled in the past 15
years, population suicide rates have fallen.
If the risks of SSRI associated suicidal behaviour
seen in children were to apply to suicide in adults,
the number of “antidepressant induced” suicides
would be small enough to be masked by currently
favourable suicide trends
Long term studies are required to assess the risks
and benefits to population health of recent large
scale rises in antidepressant prescribing.
A figure showing trends in suicide and prescribing plus further
data on the model are on bmj.com
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